Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Scar Condition and Fibrosis of the Skin Clear all
Terminated Phase 4 Interventional Results available

Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer

NCT01459666
View directory record Official record
Conditions
Scar
Interventions
Dysport (abobotulinumtoxinA), Bacteriostatic 0.9% Sodium Chloride (vehicle)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Cleveland, Ohio • Westlake, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 2, 2026, 7:53 PM EDT
Withdrawn Not applicable Interventional

Acne Scarring in Skin of Color: Laser vs Microneedling

NCT03395678
View directory record Official record
Conditions
Acne Vulgaris, Scar
Interventions
Microneedling, Fractional non-ablative 1,540nm laser
Device
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Not applicable Interventional

UVA1 Light for Treatment of Scleroderma and Similar Conditions

NCT00476801
View directory record Official record
Conditions
Scleroderma, Keloids, Other Fibrosing Conditions
Interventions
German manufactured UVA1 light emitting device
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Post-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of Keloids

NCT04710719
View directory record Official record
Conditions
Keloid, Keloid Scar Following Surgery
Interventions
Triamcinolone Injection, Triamcinolone Injection and 5-fluorouracil injection
Drug
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

NCT04827875
View directory record Official record
Conditions
Keloid, Scar, Incision, Excision Margin
Interventions
AIV001
Drug
Lead sponsor
AiViva BioPharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Encinitas, California • Coral Gables, Florida • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

NCT02079168
View directory record Official record
Conditions
Keloid
Interventions
RXI-109, Placebo
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 2, 2026, 7:53 PM EDT
Withdrawn Not applicable Interventional

Efficacy of Spray Silicone in Alteration of Burn Scar

NCT01075165
View directory record Official record
Conditions
Burn Scar
Interventions
silicone spray, saline spray
Other
Lead sponsor
United States Army Institute of Surgical Research
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation

NCT03887377
View directory record Official record
Conditions
Scar, Hypertrophic Scar, Mammary Disorder
Interventions
Botulinum Toxins, Normal saline
Drug · Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Not applicable Interventional

"A Clinical Study Investigating the Effectiveness of OTC Scar-management Modalities"

NCT04169490
View directory record Official record
Conditions
Scar, Keloid, Hypertrophic Scar, Cicatrix
Interventions
Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer, Active Comparator Onion Skin Extract Gel (Mederma), Active Comparator Silicone Gel (Kelo-Cote), Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer
Other
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids

NCT00587587
View directory record Official record
Conditions
Keloid
Interventions
Apligraf, Standard dressing regimen
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of Juvista When Administered Following Excision of Ear Lobe Keloids

NCT00710333
View directory record Official record
Conditions
Keloid
Interventions
Avotermin, placebo
Drug
Lead sponsor
Renovo
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Not applicable Interventional

A Randomized Control Trial for Preventative Scar Management

NCT01602458
View directory record Official record
Conditions
Hypertrophic Scarring
Interventions
Silicone Only Therapy (SOT), Silicone Pressure Garment Therapy (SPGT)
Procedure
Lead sponsor
Seton Healthcare Family
Other
Eligibility
1 Year to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 2, 2026, 7:53 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Skin Elasticity Measurements of the Face and Surgical Scars Stratified by Age and Skin Type

NCT01688063
View directory record Official record
Conditions
Skin Scarring, Skin Elasticity
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional

Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids

NCT00836147
View directory record Official record
Conditions
Keloid
Interventions
Avotermin (Juvista), Placebo
Drug
Lead sponsor
Renovo
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 28, 2010 · Synced Oct 2, 2026, 7:53 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy Evaluation of the Mosaic Ultra Device

NCT06117293
View directory record Official record
Conditions
Skin Texture Disorder, Photoaging, Wrinkle, Scar, Stretch Mark, Acne Vulgaris, Hair Loss
Interventions
Mosaic
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Lincolnshire, Illinois • Billerica, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars

NCT01789346
View directory record Official record
Conditions
Scar, Surgical Scar, Cicatrix, Cicatrix, Hypertrophic, Keloid
Interventions
532nm KTP, 595nm PDL
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 2, 2026, 7:53 PM EDT
Not listed Phase 2 Interventional

Treatment of Hypopigmented Scars With Bimatoprost

NCT06122090
View directory record Official record
Conditions
Scars, Hypopigmented Scar, Hypopigmented Skin, Burn Scar, Scarring, Cicatrix, Hypertrophic, Cicatrix, Pigmentation Disorder, Burns Laser
Interventions
Bimatoprost, Saline
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Not applicable Interventional Results available

Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids

NCT02996097
View directory record Official record
Conditions
Keloid
Interventions
The Lutronic electronic carbon dioxide (eCO2) Plus laser system, Intralesional Triamcinolone Acetonide
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Outcomes Following Intralesional Corticosteroid Injections

NCT03630198
View directory record Official record
Conditions
Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions
Corticosteroid with lidocaine, Corticosteroid with normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids

NCT05128383
View directory record Official record
Conditions
Keloid
Interventions
Dupilumab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 2, 2026, 7:53 PM EDT
Terminated No phase listed Observational

Keloid Tissue Bank

NCT01425437
View directory record Official record
Conditions
Keloid
Interventions
Not listed
Lead sponsor
Tirgan, Michael H., M.D.
Individual
Eligibility
13 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Device for Improving Skin Quality and Texture on the Face and Neck

NCT06645366
View directory record Official record
Conditions
Wrinkle, Pigmentation, Skin Laxity, Skin Scarring
Interventions
Treatment with BTL-785F
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
22 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Greenwood Village, Colorado • Chevy Chase, Maryland • Birmingham, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 2, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

NCT00892723
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Pasadena, California • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 2, 2026, 7:53 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety and Efficacy of Candela Technology

NCT06202274
View directory record Official record
Conditions
Hair Reduction, Tattoo Removal, Wrinkle, Acne, Scars, Benign Cutaneous Vascular Lesions, Skin Conditions
Interventions
Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Jacksonville, Florida • Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 2, 2026, 7:53 PM EDT